(Q37865381)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21494257%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

review article

1 reference

title

Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21494257%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1 reference

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21494257%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Richard A. Franklin

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21494257%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Marco Donia

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21494257%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Paolo Fagone

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21494257%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Camilla Evangelisti

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21494257%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

James A. McCubrey

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21494257%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Ferdinando Nicoletti

1 reference

ORCID Public Data File 2021

author name string

L S Steelman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21494257%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

S L Abrams

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21494257%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

W Chappell

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21494257%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

C R Kempf

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21494257%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

J Bäsecke

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21494257%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

F Stivala

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21494257%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

F Nicoletti

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21494257%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

P Ruvolo

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21494257%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

V Ruvolo

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21494257%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

A M Martelli

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21494257%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

publication date

15 April 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21494257%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21494257%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21494257%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

page(s)

1080-1094

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21494257%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21494257%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/leu.2011.66

28 January 2020

exact match

0 references

cites work

Activation of the calcium/calmodulin-dependent protein kinases as a consequence of oxidative stress.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Targeting the leukemic stem cell: the Holy Grail of leukemia therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

21 January 2018

Emerging Raf inhibitors.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

21 January 2018

Emerging MEK inhibitors.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Ras subcellular localization defines extracellular signal-regulated kinase 1 and 2 substrate specificity through distinct utilization of scaffold proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Targeting RAS signalling pathways in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Insulin receptor substrate-1/SHP-2 interaction, a phenotype-dependent switching machinery of insulin-like growth factor-I signaling in vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

MEKK1 phosphorylates MEK1 and MEK2 but does not cause activation of mitogen-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Transcriptional regulation by MAP kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Differential abilities of activated Raf oncoproteins to abrogate cytokine dependency, prevent apoptosis and induce autocrine growth factor synthesis in human hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Differential abilities of the Raf family of protein kinases to abrogate cytokine dependency and prevent apoptosis in murine hematopoietic cells by a MEK1-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

A conditionally-active form of MEK1 results in autocrine tranformation of human and mouse hematopoietic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Combined effects of aberrant MEK1 activity and BCL2 overexpression on relieving the cytokine dependency of human and murine hematopoietic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Synergy between Raf and BCL2 in abrogating the cytokine dependency of hematopoietic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Effects of inducible MEK1 activation on the cytokine dependency of lymphoid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Identification of novel in vivo Raf-1 phosphorylation sites mediating positive feedback Raf-1 regulation by extracellular signal-regulated kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Regulation of Raf-1 by direct feedback phosphorylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Identification of novel ERK-mediated feedback phosphorylation sites at the C-terminus of B-Raf

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

A Mek1-Mek2 heterodimer determines the strength and duration of the Erk signal

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

SOS phosphorylation and disassociation of the Grb2-SOS complex by the ERK and JNK signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Phosphatase and feedback regulation of Raf-1 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Regulation of the Raf-MEK-ERK pathway by protein phosphatase 5

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

A hidden oncogenic positive feedback loop caused by crosstalk between Wnt and ERK pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

MP1: a MEK binding partner that enhances enzymatic activation of the MAP kinase cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Conferring specificity on the ubiquitous Raf/MEK signalling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Coordinating ERK/MAPK signalling through scaffolds and inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Raf kinase inhibitor protein regulation of raf and MAPK signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Molecular pathways leading to oxidative stress-induced phosphorylation of Akt.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Calcium/calmodulin-dependent protein kinases as potential targets in cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Incidence and significance of FLT3-ITD and NPM1 mutations in patients with normal karyotype acute myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Internal tandem duplication of fms-like tyrosine kinase 3 is associated with poor outcome in patients with myelodysplastic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

FLT3 mutations in childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

RAS oncogene mutations and outcome of therapy for childhood acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

The T1790A BRAF mutation (L597Q) in childhood acute lymphoblastic leukemia is a functional oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Mutations in the BRAF and N-ras genes in childhood acute lymphoblastic leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Genetics of therapy-related myelodysplasia and acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Leukemia in Cardio-facio-cutaneous (CFC) syndrome: a patient with a germline mutation in BRAF proto-oncogene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

RAF translocations expand cancer targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Mechanism of suppression of the Raf/MEK/extracellular signal-regulated kinase pathway by the raf kinase inhibitor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Activation of Raf-1 signaling by protein kinase C through a mechanism involving Raf kinase inhibitory protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Regulation of RKIP binding to the N-region of the Raf-1 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

The RKIP (Raf-1 Kinase Inhibitor Protein) conserved pocket binds to the phosphorylated N-region of Raf-1 and inhibits the Raf-1-mediated activated phosphorylation of MEK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Positive- and negative-feedback regulations coordinate the dynamic behavior of the Ras-Raf-MEK-ERK signal transduction pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Snail is a repressor of RKIP transcription in metastatic prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Raf kinase inhibitor protein interacts with NF-kappaB-inducing kinase and TAK1 and inhibits NF-kappaB activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Raf-1 kinase inhibitor protein: structure, function, regulation of cell signaling, and pivotal role in apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

The role of Raf kinase inhibitor protein (RKIP) in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Reduction of Raf-1 kinase inhibitor protein expression correlates with breast cancer metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Regulation of tumor cell sensitivity to TRAIL-induced apoptosis by the metastatic suppressor Raf kinase inhibitor protein via Yin Yang 1 inhibition and death receptor 5 up-regulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

RKIP sensitizes prostate and breast cancer cells to drug-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Pivotal roles of snail inhibition and RKIP induction by the proteasome inhibitor NPI-0052 in tumor cell chemoimmunosensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Loss of RAF kinase inhibitor protein is a somatic event in the pathogenesis of therapy-related acute myeloid leukemias with C-RAF germline mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Induction of bcl-2 expression by phosphorylated CREB proteins during B-cell activation and rescue from apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

The role of Bcl-2 family proteins in chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

The Bcl-2 family as a rational target for the treatment of B-cell chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Serine/threonine phosphorylation in cytokine signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Survival factor-induced extracellular signal-regulated kinase phosphorylates BIM, inhibiting its association with BAX and proapoptotic activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Lyn kinase-dependent regulation of miR181 and myeloid cell leukemia-1 expression: implications for drug resistance in myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

MCL-1-dependent leukemia cells are more sensitive to chemotherapy than BCL-2-dependent counterparts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Evidence that Ser87 of BimEL is phosphorylated by Akt and regulates BimEL apoptotic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene-targeted therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

The emerging roles of forkhead box (Fox) proteins in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Beta1 integrin mediated adhesion increases Bim protein degradation and contributes to drug resistance in leukaemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

The bone marrow microenvironment as a sanctuary for minimal residual disease in CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Bone marrow microenvironment and the identification of new targets for myeloma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Downregulation of Bim, a proapoptotic relative of Bcl-2, is a pivotal step in cytokine-initiated survival signaling in murine hematopoietic progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Drug resistance in mutant FLT3-positive AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

IκB kinase overcomes PI3K/Akt and ERK/MAPK to control FOXO3a activity in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Targeting the eukaryotic translation initiation factor 4E for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

New modes of translational control in development, behavior, and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Dissecting eIF4E action in tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Phosphorylation of the cap-binding protein eukaryotic translation initiation factor 4E by protein kinase Mnk1 in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

MNK, EIF4E and targeting translation for therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Combined deficiency for MAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Syk-dependent mTOR activation in follicular lymphoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Mammalian target of rapamycin activator RHEB is frequently overexpressed in human carcinomas and is critical and sufficient for skin epithelial carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Tumorigenic activity and therapeutic inhibition of Rheb GTPase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Further evidence that ribavirin interacts with eIF4E

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Paradoxical activation of Raf by a novel Raf inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Targeting the Raf kinase cascade in cancer therapy--novel molecular targets and therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Mechanisms of drug inhibition of signalling molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Genetic predictors of MEK dependence in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

MEK1 mutations confer resistance to MEK and B-RAF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Inherited predispositions and hyperactive Ras in myeloid leukemogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

Reactive oxygen intermediates and signaling through kinase pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

7 January 2021

Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

7 January 2021

A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

7 January 2021

BRAF mutations are very rare in B- and T-cell pediatric acute lymphoblastic leukemias

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

7 January 2021

Mutations of the PTPN11 gene in therapy-related MDS and AML with rare balanced chromosome translocations

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

7 January 2021

Mathematical Modeling of the Influence of RKIP on the ERK Signaling Pathway

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

7 January 2021

Bcl-2, bax and bcl-xL expression in human sensitive and resistant leukemia cell lines

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

7 January 2021

Regulatory phosphorylation of Bim: sorting out the ERK from the JNK

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

7 January 2021

Relapse in children with acute lymphoblastic leukemia involving selection of a preexisting drug-resistant subclone

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.66

7 January 2021